Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Paclitaxel 10Surveys and Questionnaires 6Cisplatin 6Carboplatin 5pembrolizumab 4Brachytherapy 4Hyperthermic Intraperitoneal Chemotherapy 3Gemcitabine 3Doxorubicin 3Docetaxel 3olaparib 2niraparib 2durvalumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Music Therapy 2Mitomycin 2Letrozole 2Imagery, Psychotherapy 2Hysterectomy 2Exercise 2Everolimus 2Blood Specimen Collection 2ulipristal acetate 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Uterine Neoplasms × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡